Logo do repositório
 
Miniatura indisponível
Publicação

Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat

Utilize este identificador para referenciar este registo.

Orientador(es)

Resumo(s)

Recently, erythropoietin was shown to have both hematopoietic as well as tissue-protective properties. Erythropoietin (EPO) had a protective effect in animal models of cerebral ischemia, mechanical trauma of the nervous system, myocardial infarction, and ischemia-reperfusion (I/R) injury of the kidney. It is not known whether EPO protects the liver against I/R injury. Using a rat model of liver I/R injury, we aimed to determine the effect of the administration of human recombinant erythropoietin (rhEPO) on liver injury. Rats were subjected to 30 min of liver ischemia followed by 2 h of reperfusion. When compared with the sham-operated rats, I/R resulted in significant rises in the serum levels of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gamma-glutamyl transferase, tissue lipid peroxidation, caspase-3 activity and altered histology. Administration of rhEPO 5 min before ischemia was able to reduce the biochemical evidence of liver injury; however, this protection was not evident when rhEPO was administered 5 min before reperfusion. Mechanistically, early administration of rhEPO was able to reduce the oxidative stress and caspase-3 activation, suggesting the subsequent reduction of apoptosis. This study provides the first evidence that rhEPO causes a substantial reduction of the liver injury induced by I/R in the rat.

Descrição

Palavras-chave

Surgery Transplantation

Contexto Educativo

Citação

TRANSPLANT INTERNATIONAL. - Vol. 19, n. 11 (NOV 2006), p. 919-926

Projetos de investigação

Unidades organizacionais

Fascículo

Editora

BLACKWELL PUBLISHING

Licença CC

Métricas Alternativas